Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance

Companies developing treatments for early Alzheimer’s Disease submitted another round of positive comments last week on US Food and Drug Administration (FDA) draft guidance, offering a hint of optimism in a space where no company has seen success.